2025
-
SABCS Snippets: Results of the WISDOM 1.0 Trial
Symposium Co-director Virginia Kaklamani, MD, talks with Laura Esserman, MD, about the results of the WISDOM 1.0 study, which demonstrated that a risk-based approach to breast cancer screening is safe and acceptable to women and can improve breast cancer early detection and prevention by identifying the highest risk women who should be screened more frequently…
-
SABCS Snippets: Results of the AXSANA/EUBREAST 3 Study
Saba Shaikh, MD, talks with Thorsten Kühn, PhD, about the AXSANA/EUBREAST 3 study, which showed that, in patients who convert from clinically node-positive to node-negative breast cancer, less invasive surgical staging procedures are associated with a low axillary recurrence rate. These findings reinforce efforts to minimize surgical morbidity without compromising oncologic outcomes.
-
SABCS Snippets: Endocrine Therapy
Virginia Kaklamani, MD, talks with Hope Rugo, MD, about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study.
-
View from the Trenches panelists place SABCS presentations into clinical context
Experts wrapped up the 2025 San Antonio Breast Cancer Symposium by discussing how to translate the week’s presentations into immediate impact for patients and physicians.
-
Special session explores key distinctions, considerations around breast cancer in young women
Panelists reviewed the biological features, treatment decisions, and ethical nuances around young-onset breast cancer.
-
FDA session offers closer look at approval process for HR-positive metastatic breast cancer therapies
Participants discussed regulatory considerations for imlunestrant, datopotamab deruxtecan (Dato-DXd), and trastuzumab deruxtecan (T-DXd).
-
AACR Outstanding Investigator Awardee reflects on lessons from working toward personalized medicine
Sara M. Tolaney, MD, MPH, emphasized the importance of always putting patients first, both as a researcher and a clinician.
-
Third General Session features supportive interventions for survivors, menopausal hormone therapy risk analysis, and more
Joanne Kotsopoulos, PhD; Ann H. Partridge, MD, MPH; and Jun J. Mao, MD, MSCE, were among the experts reporting findings Friday during the final General Session at the San Antonio Breast Cancer Symposium.
-
Plenary lecturer reviews work to enhance understanding of BRCA1/2-mediated tumorigenesis
Joan Brugge, PhD, shared new insights into breast tumorigenesis in BRCA1/2-mutation carriers.
-
AACR Distinguished Lectureship recipient shares goals for future applications of ctDNA detection
Ben Ho Park, MD, PhD, discussed the potential of circulating tumor DNA (ctDNA) to transform adjuvant treatment for breast cancer.